
Opinion|Videos|May 19, 2025
Treatment or Lack of Treatment of Small Renal Masses
Explore treatment options for small renal masses, including surveillance, surgery, and biopsy, while understanding the role of ccRCC PET in diagnosis.
Advertisement
Episodes in this series

Treatment Approaches and Role of Biopsy
Main Discussion Topics:
- Masses under 2 cm are typically managed with active surveillance.
- Options for masses that are 2 to 4 cm include ablation (eg, cryotherapy, radiofrequency ablation) and surgical approaches.
- Kidney cancer is often treated without tissue diagnosis, unlike most other cancers.
- Biopsy utilization depends on tumor characteristics and management implications.
Key Points for Physicians:
- Small masses (< 2cm) are generally appropriate for active surveillance.
- Approximately 60% to 70% of small renal masses are malignant.
- Biopsy is considered for unusual lesions, suspected metastases, or infiltrative patterns.
- Risk stratification can be enhanced by considering patient age, gender, and tumor size.
Notable Insights:
Kidney cancer remains one of the few cancers typically treated without tissue confirmation, though this approach is increasingly being questioned.
Clinical Significance:
Size-based management algorithms provide practical guidance, but patient-specific factors and tumor characteristics should inform individualized treatment decisions.
Advertisement
Related to this article

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.

Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement

